Longitudinal genetically detectable minimal residual disease by fluorescence <i>in situ</i> hybridization confers a poor prognosis in myeloma.

"KCA serves on advisory boards to Pfizer, Amgen, AstraZeneca, Janssen, Precision Biosciences, Window, and Starton, and is a scientific founder of OncoPep, C4 Therapeutics, Raqia, and NextRNA. All other authors declared no potential conflict of interest."

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We thank all the patients and families for participating in this research study. This investigation was supported by the National Natural Science Foundation (grants 82270218, U22A20291, to G. An; grant 32100656 to X. Dong), the CAMS Innovation Fund for Medical Sciences (CIFMS) (grants 2022-I2M-1-022, to L. Qiu; grant 2021-I2M-C&T-B-079, to G. An; grants 2021-I2M-1-041), the International Cooperation Projects of National Natural Science Foundation (grants 81920108006, to L. Qiu). J. Cui is supported by grant from International Myeloma Society."